Primary gamma-herpesviral infection in Zambian children.
BACKGROUND
HHV-8 is closely related to Epstein-Barr virus (EBV), but the clinical presentations of these two infections in early childhood are not well understood. Also, it is not known whether infection by one virus correlates with another. Here, we compare the natural history of infection by these two viruses along with the clinical manifestations and risk factors that are associated with early childhood infection in Zambia, which is an endemic area for HHV-8.


METHODS
This study was conducted in a cohort of 12 month old Zambian children (N = 677). Data on socio-economic status and a wide range of clinical manifestations were collected. Logistic regression was used to test for significant associations between the collected variables and HHV-8 or EBV serostatus at 12 months of age.


RESULTS
We observed a significantly higher seroprevalence for EBV (58.9%) as compared to HHV-8 (13.4%). HIV-1 infected children had at a significantly higher risk of being infected with HHV-8 (Odds ratio [OR] 3.69, 95% confidence interval [CI] 1.64 - 8.32). HIV-1 infection of the mothers was a significant risk factor for increased acquisition of EBV but not HHV-8 by children (OR 1.86, 05% CI 1.20 - 2.87). Self reported rash was marginally associated with primary infection for HHV-8 and EBV.


CONCLUSIONS
These results suggest that there is no correlation between EBV and HHV-8 infections. Infection by one does not increase the susceptibility for the second virus. Primary HHV-8 and EBV infection in early childhood may clinically present as rash but remains largely asymptomatic and may remain undetected in this population. HIV infection in the mother or child are important risk factors that contribute to EBV or HHV-8 infection.
Minhas
Veenu
V
Nebraska Center for Virology and School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583 USA.
Brayfield
Brad P
BP
Crabtree
Kay L
KL
Kankasa
Chipepo
C
Mitchell
Charles D
CD
Wood
Charles
C
D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000453:epidemiology; D006566:Herpesviridae Infections / Q000453:epidemiology* / Q000473:pathology / Q000821:virology*; D004854:Herpesvirus 4, Human / Q000302:isolation & purification*; D019288:Herpesvirus 8, Human / Q000302:isolation & purification*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009035:Mothers; D012307:Risk Factors; D015024:Zambia / Q000453:epidemiology
J Infect Dis. 2006 Feb 1;193(3):422-6
16388490
Semin Oncol. 2001 Apr;28(2):198-206
11301383
J Infect Dis. 1998 Apr;177(4):1087-90
9534989
Arch Dis Child. 1995 Aug;73(2):100-4; discussion 104-5
7574850
J Infect Dis. 2006 Apr 1;193(7):971-7
16518759
J Med Virol. 1985 Jan;15(1):11-6
2981976
Science. 1994 Dec 16;266(5192):1865-9
7997879
J Infect Dis. 2004 Jun 15;189(12):2260-70
15181574
Lancet. 1999 Oct 2;354(9185):1141-2
10513704
J Clin Microbiol. 2006 Jul;44(7):2409-15
16825357
East Afr Med J. 1996 May;73(5 Suppl):S29-30
8756025
PLoS Pathog. 2007 Jun;3(6):e80
17559303
Int J Cancer. 2008 Mar 15;122(6):1319-23
18000823
J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):474-9
15764964
J Trop Med Hyg. 1995 Aug;98(4):281-4
7636927
Nat Rev Cancer. 2004 Oct;4(10):757-68
15510157
Lancet. 1995 Mar 25;345(8952):759-61
7891487
Clin Vaccine Immunol. 2008 Aug;15(8):1259-64
18508931
J Virol. 2007 Jun;81(11):6068-78
17376914
J Virol. 2002 Oct;76(20):10427-36
12239319
JAMA. 2002 Mar 13;287(10):1295-300
11886321
Am J Epidemiol. 2008 Aug 1;168(3):311-20
18515794